Bristol-Myers Squibb (NYS: BMY) Demonstrates breakthrough oncology data at Asco 2025 Meeting
Bristol-Myers Squibb is entering oncology, confirming future reports in 2025. At the ASCO Annual Meeting, which emphasizes a great deal of attention to the treatment of cancer. This coincided with 2.66% of the increase in its share price last week. The company’s progress has included new research on several oncology portfolio, which could attract investors’ … Read more